Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enobosarm and Anastrozole for High Mammographic Breast Density
NCT03264651Phase 1Completed
- Sponsor
- Havah Therapeutics
- Start
- Feb 2017
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of enobosarm in breast cancer, sponsored by Havah Therapeutics. Primary endpoints: Mammographic breast density at 12 months and Breast tissue elasticity at 6 months. Started Feb 2017; status: completed.
02
Drugs
enobosarm
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03264651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03264651.